Join us for a one-hour discussion about HEMLIBRA (emicizumab) and its use in people with hemophilia A with or without factor VIII inhibitors. This program will be presented by Bobbi Sellers, who will discuss the dosing regimen, efficacy and safety profile of HEMLIBRA. It will feature a HEMLIBRA Connections ambassador telling their story and answering questions. We invite you to join what promises to be a robust and engaging dialogue! Click here for the event flyer.
RSVP to email@example.com by October 24
This program is sponsored and presented by